Montreal, February 19, 2018 – Pendopharm a division of Pharmascience Inc. signs an agreement with Cosmo Pharmaceuticals, an Irish specialty pharmaceutical company, which is one of the world leaders in the field of gastrointestinal diseases.
This excellent strategic opportunity is directly related to Pendopharm’s most prolific therapeutic class, gastroenterology. The agreement includes four products, one of which has two possible indications, which will enable Pendopharm to launch several innovative products for the Canadian market in the coming years. The products are:
- Eleview: A volumizing agent designed to lift polyps and keep them elevated for safe and complete resection;
- Methylene Blue MMX: A coloring agent allowing the staining of the mucosa prior to colonoscopy thus enhancing the detection of pre-cancerous lesions or polyps in the colon;
- Rifamycin SV MMX: A broad spectrum, semi-synthetic, orally non-absorbable antibiotic which can be used for the treatment of bacterial infections of the colon such as traveler’s diarrhea;
- Qolotag: An enema used for the mechanical cleansing, and simultaneous staining, of the sigmoid colon and rectum in order to facilitate the detection of lesions on the mucosa.
“We are very happy to have concluded this agreement with Cosmo Pharmaceuticals, which will allow Canadian patients to benefit from quality products in demand. The addition of these products to Pendopharm’s gastroenterology portfolio will, among other things, strengthen its position in the marketplace and take a step toward becoming an established leader in the world of gastroenterology. These additions will also play an important role in the prevention of colorectal cancer through increased detection, a noble cause that is important to us.” said Dr. David Goodman, Chief Executive Officer of Pharmascience.
About Pharmascience Inc.
Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with over 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 60 countries. Pharmascience Inc. has strong long-standing philanthropic ties with its communities, both locally and internationally. For more than 20 years, Pharmascience has been working through Health Partners International of Canada (HPIC) as the partner of choice to increase access to medicine. Pharmascience’s total donations of essential medicine are close to $60 million. Pharmascience Inc. is a leading manufacturer and marketer of prescription, generic, over-the-counter and behind-the-counter products, as well as FDA-approved Canadian-made injectables. Pharmascience Inc. commercializes nearly 400 product families in 20 different dosage forms for over 2,000 products. In Canada alone, more than 45 million prescriptions a year are filled with Pharmascience products. For more information, please visit www.pharmascience.com.